AXSOME THERAPEUTICS, INC. Selling and Marketing Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Selling and Marketing Expense of $164.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2026-06-30 was $164.11M, a 65.14% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2026-03-31 was $146.44M, a 58.67% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2025-12-31 was $134.54M, a 69.41% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2025-09-30 was $114.20M, a 67.48% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for fiscal 2025 was $440.40M, a 50.13% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for fiscal 2024 was $293.36M, a 23.66% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for fiscal 2023 was $237.23M, a 126.67% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. selling and marketing expense for fiscal 2022 was $104.66M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $164.11M 10-Q · filed 2026-08-10 | $310.55M 10-Q · filed 2026-08-10 | $445.09M derived: sum of 3 quarters · filed 2026-08-10 | $559.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $146.44M 10-Q · filed 2026-05-04 | $280.98M derived: sum of 2 quarters · filed 2026-05-04 | $395.18M derived: sum of 3 quarters · filed 2026-05-04 | $494.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $134.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $248.74M derived: sum of 2 quarters · filed 2026-02-23 | $348.11M derived: sum of 3 quarters · filed 2026-08-10 | $440.40M 10-K · filed 2026-02-23 |
| 2025-09-30 | $114.20M 10-Q · filed 2025-11-03 | $213.58M derived: sum of 2 quarters · filed 2026-08-10 | $305.86M 10-Q · filed 2025-11-03 | $385.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $99.38M 10-Q · filed 2026-08-10 | $191.66M 10-Q · filed 2026-08-10 | $271.08M derived: sum of 3 quarters · filed 2026-08-10 | $339.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $92.29M 10-Q · filed 2026-05-04 | $171.71M derived: sum of 2 quarters · filed 2026-05-04 | $239.89M derived: sum of 3 quarters · filed 2026-05-04 | $314.45M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $79.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $147.60M derived: sum of 2 quarters · filed 2026-02-23 | $222.16M derived: sum of 3 quarters · filed 2026-02-23 | $293.36M 10-K · filed 2026-02-23 |
| 2024-09-30 | $68.19M 10-Q · filed 2025-11-03 | $142.74M derived: sum of 2 quarters · filed 2025-11-03 | $213.94M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $74.56M 10-Q · filed 2025-08-04 | $145.75M 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $71.20M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $237.23M 10-K · filed 2026-02-23 | |||
| 2022-12-31 | $104.66M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |